Candidate aids vaccines

New England Journal of Medicine

Volumn 333, Issue 20, 1995, Pages 1331-1339

  Wood, Alastair J J ^a   Graham, Barney S ^a,b   Wright, Peter F ^a,b  

^a Departments of Medicine   (United States)

^b Departments of Microbiology and Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN DETECTION; CYTOTOXIC T LYMPHOCYTE; DRUG ANTIGENICITY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS RECOMBINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMAL; CLINICAL TRIALS; HIV ANTIBODIES; HIV-1; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028839622     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199511163332007     Document Type: Review

References (100)

1. Fenner F, Henderson DA, Arita I, Ječek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988.
2. Wright PF, Kim-Farley RJ, de Quadros CA, Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991; 325: 1774-1779
3. Wei X, Ghosh SK, Taylor ME, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
5. Emini EA, Schleif WA, Nunberg JH, Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355: 728-730
6. Putkonen P, Thorstensson R, Ghavamzadeh L, Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991; 352: 436-438
7. Prince AM, Reesink H, Pascual D, Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991; 7: 971-973
8. Ada GL The immunological principles of vaccination. Lancet 1990; 335: 523-526
9. Hanson CV Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res Hum Retroviruses 1994; 10: 645-648
10. Graham BS, Rowland JM, Modliszewski A, Montefiori DC Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. J Clin Microbiol 1990; 28: 2608-2611
11. Brenner TJ, Dahl KE, Olson B, Miller G, Andiman WA Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children. Lancet 1991; 337: 1001-1005
12. Tyler DS, Stanley SD, Nastala CA, Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection: humoral and cellular defects. J Immunol 1990; 144: 3375-3384
13. Miller CJ, McGhee JR, Gardner MB Mucosal immunity, HIV transmission and AIDS. Lab Invest 1993; 68: 129-145
14. Lin YL, Askonas BA Biological properties of an influenza A virus-specific killer T cell clone: inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions. J Exp Med 1981; 154: 225-234
15. Byrne JA, Oldstone MB Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol 1984; 51: 682-686
16. Koup RA, Safrit JT, Cao Y, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655
17. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110
18. Reimann KA, Tenner-Racz K, Racz P, Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994; 68: 2362-2370
19. Rowland-Jones S, Sutton J, Ariyoshi K, HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64
20. Balfe P, Simmonds P, Ludlam CA, Bishop JO, Brown AJ Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J Virol 1990; 64: 6221-6233
21. LaRosa GJ, Davide JP, Weinhold K, Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249: 932-935 [Erratum, Science 1991;251:811.]
22. Wolfs TFW, Zwart G, Bakker M, Goudsmit J HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992; 189: 103-110
23. Preston BD, Poiesz BJ, Loeb LA Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168-1171
24. Nara PL, Smit L, Dunlop N, Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 1990; 64: 3779-3791
25. Phillips RE, Rowland-Jones S, Nixon DF, Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354: 453-459
26. Cichutek K, Merget H, Norley S, Development of a quasispecies of human immunodeficiency virus type 1 in vivo. Proc Natl Acad Sci U S A 1992; 89: 7365-7369
27. Korber B, Wolinsky S, Haynes B, HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992; 8: 1461-1465
28. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993; 67: 2182-2190
29. Zhu T, Mo H, Wang N, Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181
30. Shafferman A, Jahrling PB, Benveniste RE, Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A 1991; 88: 7126-7130
31. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 1991; 254: 105-108
32. Townsend ARM, Gotch FM, Davey J Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985; 42: 457-462
33. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, McMichael AJ HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336: 484-487
34. Gardner MB Vaccination against SIV infection and disease. AIDS Res Hum Retroviruses 1990; 6: 835-846
35. Desrosiers RC, Wyand MS, Kodama T, Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A 1989; 86: 6353-6357
36. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-1941
37. Murphey-Corb M, Martin LN, Davison-Fairburn B, A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989; 246: 1293-1297
38. Johnson PR, Montefiori DC, Goldstein S, Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A 1992; 89: 2175-2179
39. Girard M, Kieny M-P, Pinter A, Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 1991; 88: 542-546
40. Fultz PN, Nara P, Barre-Sinoussi F, Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992; 256: 1687-1690
41. Stott EJ Anti-cell antibody in macaques. Nature 1991; 353: 393-393
42. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP The ability of certain SIV vaccines to provoke reactions against normal cells. Science 1992; 255: 292-293
43. Cranage MP, Polyanskaya N, McBride B, Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993; 9: 13-22
44. Arthur LO, Bess JW Jr, Sowder RC II, Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992; 258: 1935-1938
45. Berman PW, Gregory TJ, Riddle L, Protection of chimpanzees from infection of HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990; 345: 622-625
46. Hu S-L, Abrams K, Barber GN, Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255: 456-459
47. Marx PA, Compans RW, Gettie A, Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993; 260: 1323-1327
48. Desrosiers RC HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992; 8: 411-421
49. Hirsch VM, Goldstein S, Hynes NA, Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 1994; 170: 51-59
50. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 1992; 5: 639-646
51. Agy MB, Frumkin LR, Corey L, Infection of Macaca nemestrina by human immunodeficiency virus type 1. Science 1992; 257: 103-106
52. Shibata R, Hoggan MD, Broscius C, Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J Virol 1995; 69: 4453-4462
53. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM A strategy for prophylactic vaccination against HIV. Science 1993; 260: 1270-1272
54. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267: 1820-1825
55. Putkonen P, Thorstensson R, Albert J, Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990; 4: 783-789
56. George JR, Ou CY, Parekh B, Prevalence of HIV-1 and HIV-2 mixed infections in Cote d'Ivoire. Lancet 1992; 340: 337-339
57. Peeters M, Gershy-Damet GM, Fransen K, Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 1992; 340: 339-340
58. Fultz PN, Srinivasan A, Greene CR, Butler D, Swenson RB, McClure HM Superinfection of a chimpanzee with a second strain of human immunodeficiency virus. J Virol 1987; 61: 4026-4029
59. Hilleman MR, McAleer WJ, Buynak EB, McLean AA The preparation and safety of hepatitis B vaccine. J Infect 1983; 7: Suppl 1: S3-S8
60. Mackett M, Smith GL, Moss B Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 1982; 79: 7415-7419
61. Panicali D, Paoletti E Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 1982; 79: 4927-4931
62. Graham BS, Gorse GJ, Schwartz DH, Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994; 170: 782-786
63. Cox WI, Tartaglia J, Paoletti E Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993; 195: 845-850
64. Cooney EL, McElrath MJ, Cory L, Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 1993; 90: 1882-1886
65. Hammond SA, Bollinger RC, Stanhope PE, Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992; 176: 1531-1542
66. el-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ Jr Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993; 168: 306-313
67. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64: 2653-2659
68. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90: 11478-11482
69. Ulmer JB, Donnelly JJ, Parker SE, Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749
70. Warren HS, Vogel FR, Chedid LA Current status of immunological adjuvants. Annu Rev Immunol 1986; 4: 369-388
71. Mowat AMCI, Donachie AM, Reid G, Jarrett O Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-322
72. Deres K, Schild H, Wiesmuller K-H, Jung G, Rammensee H-G In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989; 342: 561-564
73. Mosmann TR, Coffman RL Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-147
74. Defoort JP, Nardelli B, Huang W, Ho DD, Tam JP Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc Natl Acad Sci U S A 1992; 89: 3879-3883
75. Palker TJ, Matthews TJ, Langlois A, Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989; 142: 3612-3619
76. Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28: 287-294
77. Cranage MP, Baskerville A, Ashworth LAE, Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 1992; 339: 273-274
78. Lehner T, Bergmeier LA, Panagiotidi C, Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 1992; 258: 1365-1369
79. Burke DS Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 1992; 35: 511-530
80. Schwartz DH Potential pitfalls on the road to an effective HIV vaccine. Immunol Today 1994; 15: 54-57
81. Lee MR, Ho DD, Gurney ME Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Science 1987; 237: 1047-1051
82. Reiher WE III, Blalock JE, Brunck TK Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2. Proc Natl Acad Sci U S A 1986; 83: 9188-9192 [Erratum, Proc Natl Acad Sci U S A 1987;84:564.]
83. Golding H, Robey FA, Gates FT III, Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II β 1 domain: I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 1988; 167: 914-923
84. Zagury JF, Bernard J, Achour A, Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis. Proc Natl Acad Sci U S A 1993; 90: 7573-7577
85. Wilks D, Walker LC, Habeshaw JA, Webster AD, Dalgleish AG Antiidiotypic responses to immunization with anti-Leu 3a in human immunodeficiency virus-seropositive individuals. J Infect Dis 1991; 163: 389-392
86. Keay S, Tacket CO, Murphy JR, Handwerger BS Anti-CD4 anti-idiotype antibodies in volunteers immunized with rgp160 of HIV-1 or infected with HIV-1. AIDS Res Hum Retroviruses 1992; 8: 1091-1098
87. Golding H, Shearer GM, Hillman K, Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest 1989; 83: 1430-1435
88. Keefer MC Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group: NIAID AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 1994; 10: Suppl 2: S139-S140
89. Belshe RB, Clements ML, Dolin R, Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168: 1387-1395
90. Takeda A, Robinson JE, Ho DD, Debouck C, Haigwood NL, Ennis FA Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J Clin Invest 1992; 89: 1952-1957
91. Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 1989; 244: 1357-1360
92. Robinson WE Jr, Montefiori DC, Mitchell WM Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1: 790-794
93. Porterfield JS Antibody-dependent enhancement of viral infectivity. Adv Virus Res 1986; 31: 335-355
94. Montefiori DC, Lefkowitz LB Jr, Keller RE, Holmberg V, Sandstrom E, Phair JP Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. AIDS 1991; 5: 513-517
95. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, Burke DS Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 1993; 9: 1175-1184
96. Redfield RR, Birx DL, Ketter N, A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324: 1677-1684
97. Belshe RB, Clements ML, Keefer MC, Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. Ann Intern Med 1994; 121: 584-589
98. Pincus SH, Messer KG, Schwartz DH, Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993; 91: 1987-1996
99. Montefiori DC, Graham BS, Zhou JT, V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. J Clin Invest 1993; 92: 840-847
100. World Health Organization. Scientific and public health rationale for HIV vaccine efficacy trials. AIDS 1995; 9: WHO1-WHO4